Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
August-2017 Volume 14 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August-2017 Volume 14 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma

  • Authors:
    • Xiao‑Nu Peng
    • Jing Wang
    • Wei Zhang
  • View Affiliations / Copyright

    Affiliations: Department of Thoracic Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Intensive Care Unit, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China
    Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 2249-2253
    |
    Published online on: June 15, 2017
       https://doi.org/10.3892/ol.2017.6387
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Non‑small cell lung cancer etiology and its treatment failure are due to epidermal growth factor receptor (EGFR) kinase domain mutations at amino acid position 790. The mutational change from threonine to methionine at position 790 (T790M) is responsible for tyrosine kinase inhibition failure. Using molecular dynamic simulation, the present study investigated the architectural changes occurring at the atomic scale. The 50‑nsec runs using a GROMOS force field for wild‑type and mutant EGFR's kinase domains were investigated for contrasting variations using Gromacs inbuilt tools. The adenosine triphosphate binding domain and the active site of EGFR were studied extensively in order to understand the structural changes. All the para­meters investigated in the present study revealed considerable changes in the studied structures, and the knowledge gained from this may be used to develop novel kinase inhibitors that will be effective irrespective of the structural alterations in kinase domain.

Introduction

Lung cancer is the most commonly diagnosed type of cancer, with 1.82 million new cases diagnosed in 2012 and 1.6 million associated mortalities annually, which makes it the most common cause of cancer-associated mortality worldwide (1). Lung cancer has two primary types, small-cell lung carcinoma and non-small cell lung carcinoma (NSCLC), with NSCLC being more prevalent (2). The 5-year survival rate following initial diagnoses of patients with NSCLC is only 5–15%, which means it is the most lethal type of cancer (3). The treatment of NSCLC was linked with targeting the epidermal growth factor receptor (EGFR) by Wrann et al (4) over four decades ago. Inhibition of the EGFR signaling pathway by kinase inhibitors and monoclonal antibodies is a viable option for therapy of NSCLC (5–7).

The kinase inhibitor response to patients with NSCLC is linked to mutations in the EGFR protein, and the mutations of EGFR are classified into activating mutations and second mutations; the latter are associated with lung cancer and the former mutations cause drug resistance (8–10). The efficacy of kinase inhibitors is associated with the mutational change from threonine to methionine at amino acid position 790 (T790M); this mutation is associated with disease resistance by sterically blocking kinase inhibitors, including gefitinib and erlotinib (11–13). The location of this threonine at position 790 acts as a gatekeeper, as it is located at the entrance of a hydrophobic groove at the back of the adenosine triphosphate binding pocket (14).

Atomic insight into altered architecture due to mutations using molecular dynamic simulation (MDS) is a practice currently in use (15,16). The present study used MDS to investigate the anomalies in the gatekeeper region due to mutation from threonine to methionine. The X-ray crystallographic structure of the wild-type EGFR kinase domain with PDB ID no. 2GS2 (17) was selected for the MDS analysis. This structure and the architecture of its mutated forms were analyzed using Gromacs inbuilt tools. In order to understand the effect of mutation on the flexibility of the two structures, principle component analysis and free energy landscape analysis were performed.

Materials and methods

Protein preparation

The crystallographic structure of the tyrosine kinase domain of EGFR was retrieved from the Research Collaboratory for Structural Bioinformatics protein data bank (http://www.rcsb.org/pdb/home/home.do) and the structure with PDB ID 2GS2 (17) was used in the present study. The structure was energy minimized prior to and following insertion of mutations using the Swiss Protein Data Bank viewer (18). A total of two structures were generated; the first was the wild-type EGFR tyrosine kinase domain and the second was the tyrosine kinase domain with T790M drug-resistant mutation.

Molecular dynamics simulation

Gromacs version 4.6.6 package (19) was developed for analysis of the bimolecular systems of proteins, DNA and lipids in order to investigate the architecture of the tyrosine kinase domain of EGFR. All three systems were analyzed under a GROMOS96 43a1 force field (20). The EGFR tyrosine kinase domain was placed in a rectangular box of 15 Å marginal radius and the protein domain under investigation was placed in the center. Subsequently, the box was filled with water using the TIP3P model (21) and the system was made neutral using the Genion tool of the Gromacs package. The two systems generated were subjected to a force of 100 kcal/mol for 5,000 steps, during which the solvent molecules were relaxed and the solutes were restrained to their original position. In order to regulate the temperature inside the system, the Berendsen temperature coupling method (22) was used and the system was maintained under 1 atm pressure with allowed compressibility ranging from 4.5×10−5 atm. The system was energy minimized twice prior to position restraint simulation for 5 nsec. Following this step, the system was subjected to a 50 nsec MDS run and the results were saved following every 2 psec. In order to evaluate the alterations in architecture of the tyrosine kinase domain of EGFR protein tools, g_rms, g_rmsf, g_sas, g_hbond, g_gyrate, g_rama, g_rmsdist, g-sham and do_dssp were used. The results were visualized using Pymol (Schrödinger, Inc., New York, NY, USA) (23) and VMD (University of Illinois at Urbana-Champaign, Champaign, IL, USA) (24), and the graphs were plotted using the Grace GUI toolkit version 5.1.19 (Oregon Graduate Institute of Science and Technology, Hillsboro, OR, USA) (25).

Results

General structural changes in Kinase domain of EGFR by T790M

In order to investigate the effect of T790M mutations on the tyrosine kinase domain, the present study used the X-ray crystallographic method and the structures were subjected to MDS. The results were analyzed to investigate the anomaly in the architecture of the kinase domain. The protein structure and its function are interlinked and any change in the protein structure affects its function. In the case of EGFR, the mutations that were analyzed in the present study were responsible for the drug failure.

The pictorial representation of MDS of the two structures under observation are presented in Fig. 1; the structures under observation were stable throughout the process. The moviemaker from Pymol viewer suite was used to make the movie of the three runs with each frame of the movie retrieved following 100 psec (the movies are available on request). The basic visualization demonstrated the change in the area of the domain.

Figure 1.

Pictorial representations of the molecular dynamic simulation run of the two structures from 0–50 nsec.

In order to investigate the intricate details of the tyrosine kinase domain architecture alterations due to the mutations analyzed, the present study used various Gromacs inbuilt tools. g_rmsf was used to evaluate the root mean square fluctuation of the residues of the tyrosine kinase domain. The results are presented in Fig. 2A. T790M mutation from rmsf analysis demonstrated a distinct pattern compared with the wild-type, and the residues of importance are marked in Fig. 2A. The g_rmsf tool was also used to determine the b-factor to a file with the average coordinates; the results are presented in Fig. 2B. The spectrum ranges from blue to white to red, indicating the fluctuation in the region, with blue being the least and red being the most flexible. The mutant domain revealed the most fluctuation and the wild-type domain demonstrated the least.

Figure 2.

(A) RMSF of the EGFR wild-type (black) and mutant (red). The important residues of ATP binding and active site are marked. (B) The b-factor implicated on the average structures of the wild-type and mutant EGFR, clearly indicating the mutant structure to be more fluctuating in nature. RMSF, root mean square fluctuation; ATP, adenosine triphosphate; EGFR, epidermal growth factor receptor.

Root mean square deviation (RMSD) was evaluated using the g_rms tool, and the tool was used to compare the structures by evaluating their RMSD values. The mutant structure revealed the maximum deviation, as presented in Fig. 3A. g_rmsdist determined the RMSD of atom distances; the wild-type domain of the structure was the most stable and the mutant was the most unstable, as presented in Fig. 3B.

Figure 3.

(A) RMSD of the EGFR wild-type (black) and mutant (white), which demonstrated that the wild-type attained stability after 10 nsec and the mutant structure revealed fluctuation throughout the run. (B) The RMS distribution peak clearly demonstrated that the wild-type (black) was more stable in terms of RMS and a.u., whereas the mutant was highly unstable. RMSD, root-mean-square deviation; a.u., atomic unit.

The g_gyrate tool was used to determine the radius of gyration of the atoms in the three structures under observation, and the mutant structure revealed the maximum deviation. The mutant domain was demonstrated to decrease in the radius of gyration following a 25-nsec run (Fig. 4), indicating the decrease in size. The same trend was observed when total solvent accessible surface area (SASA) was evaluated using the g_sas tool. SASA results (Fig. 5) revealed that the mutation had a contrasting effect on the tyrosine kinase domain of EGFR, with mutation decreasing the size of the domain, hence a smaller SASA.

Figure 4.

Radius of gyration plot of the two structures for a 50-nsec run demonstrated the mutant structure decreased its size following a 20-nsec run and continued to decrease until 50 nsec. Rg, radius of gyration.

Figure 5.

Solvent accessible surface area of the mutant structure revealed a decrease compared with the wild-type. The decrease was observed following a 30-nsec run.

Intra- and interhydrogen bond pattern analysis

The intrahydrogen bond pattern of the two structures under observation was investigated using the g_hbond tool of the Gromacs package. The wild-type structure formed a mean of 203 hydrogen bonds per time frame out of a possible 164,227, and the mutant formed a mean of 201 hydrogen bonds per time frame out of possible 166,173. Fig. 6A presents a pictorial representation of the mean number of hydrogen bonds per time frame within the domains. Fig. 6B presents the hydrogen bond pattern between the protein and water; the results showed 519 and 520 bonds for the wild-type and mutant structures, respectively.

Figure 6.

(A) Intra protein hydrogen bond pattern of wild-type (and mutant revealed that the mutant had a smaller number throughout the run. The mean number of hydrogen bonds for the mutant was 201 bonds per frame and for the wild-type was 203 bonds per frame. (B) This figure presents the protein-water hydrogen bond pattern of the two structures under observation.

Secondary structure analysis

The secondary structure architecture of the protein was investigated for alterations in the layout of the domain in general. The average structure of the EGFR tyrosine kinase domain was retrieved from the two simulations, and the structures were analyzed for secondary structure architecture layout. Fig. 7 presents the three secondary structure layouts, where clear alterations can be observed in the mutant layouts when compared with the wild-type. To investigate the secondary structure changes over time, the do_dssp tool was used and the structures were retrieved following every 100 psec; the results are presented in Fig. 8.

Figure 7.

Average secondary structure layout of the simulated structures following a 50-nsec run. The mutant structure demonstrated a considerable alteration in its secondary structure architecture.

Figure 8.

Secondary structure layout of the two structures generated using do_dssp. The structures for the analysis were captured every 100 psec.

Discussion

Following mutation there is an alteration in amino acids and their basic features of size, charge and hydrophobicity value. These changes induce protein architectural alterations, which in turn affect its function, as reported by Chikan et al (15). In the present study, the change from threonine to methionine also induced these alterations; methionine is a larger residue with a greater hydrophobic property compared with wild-type threonine. Due to these changes, the mutant structure demonstrated considerable alterations in the secondary structure architecture, which revealed its effect on EGFR kinase domain size and its total polar solubility. Each of these properties demonstrated a reduced value compared with that of the wild-type structure.

The threonine at position 790 was conserved, but a few other residue types were observed at this position, including methionine. This means that homologous proteins exist with the same residue type as the mutant at this position, and this mutation is possibly not damaging to the protein. The threonine also forms hydrogen bonds with arginine at position 776; with the alteration in properties of the residue this intrahydrogen bond formation is lost, which induces the variation of intrahydrogen bond pattern in the core of the kinase domain, a change that may have an effect on tyrosine kinase inhibitor (TKI) failure. Threonine 790, the ‘gatekeeper’ residue in EGFR, has previously been suggested to cause resistance by sterically blocking the binding of known TKIs and is sensitive to structurally similar irreversible inhibitors (11). The data from the present study suggested that the intrahydrogen bond pattern in the core of the kinase domain can be a factor triggering selective inhibition of EGFR by TKIs.

The structural insight obtained regarding the kinase domain of EGFR due to T790M mutation may pave the way for novel TKI developments. Previous studies have used computational approaches to look into novel TKI development; the approach has been used to propose lead compounds that exhibit more efficient binding with mutated EGFR (26,27). Zhao et al (26) reported on T790M and L858R mutations in EGFR and their results are in accordance with the findings from the present study. The present study proposes that changing the intrahydrogen bond pattern in the core of the kinase domain serves as a base for structure-based drug sensitivity in EGFR. This may provide a basis on which novel TKI development can be achieved, where the stable mutant structure from the simulation trajectory can act as a template and novel TKI can be screened over it. The possible TKI developed using the structure-based drug designing method may inhibit the kinase activity without any effect from drug resistant mutations (26,27).

References

1 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Longo D, Fauci A, Kasper D, Hauser S, Jameson J and Loscalzo J: Harrison's Principles of Internal Medicine. 18th. McGraw-Hill Professional; New York, NY: 2011

3 

Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 125:860–865. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Wrann MM and Fox CF: Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. J Biol Chem. 254:8083–8086. 1979.PubMed/NCBI

5 

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI and Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 19:419–427. 1996. View Article : Google Scholar : PubMed/NCBI

7 

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA. 290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Johnson BE and Jänne PA: Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65:7525–7529. 2005.PubMed/NCBI

11 

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 105:pp. 2070–2075. 2008; View Article : Google Scholar : PubMed/NCBI

12 

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI

13 

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA. 102:pp. 7665–7670. 2005; View Article : Google Scholar : PubMed/NCBI

15 

Chikan N, Bukhari S, Shabir N, Amin A, Shafi S, Qadri RA and Patel TN: Atomic insight into the altered O6-Methylguanine-DNA methyltransferase protein architecture in gastric cancer. PLoS One. 10:e01277412015. View Article : Google Scholar : PubMed/NCBI

16 

Bukhari S, Mokhdomi TA, Chikan NA, Amin A, Qazi H, Wani SH, Wafai AH, Tyub S, Mustafa F, Mir MS, et al: Affinity proteomics led identification of vimentin as a potential biomarker in colon cancers: Insights from serological screening and computational modelling. Mol Biosyst. 11:159–169. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Zhang X, Gureasko J, Shen K, Cole PA and Kuriyan J: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 125:1137–1149. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Guex N and Peitsch MC: SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis. 18:2714–2723. 1997. View Article : Google Scholar : PubMed/NCBI

19 

Hess B, Kutzner C, van der Spoel D and Lindahl E: GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 4:435–447. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Schuler LD, Daura X and Van Gunsteren WF: An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase. J Comput Chem. 22:1205–1218. 2001. View Article : Google Scholar

21 

Mark P and Nilsson L: Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298K. J Phy Chem. 105:9954–9960. 2001. View Article : Google Scholar

22 

Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A and Haak JR: Molecular dynamics with coupling to an external bath. J Chem phys. 81:36841984. View Article : Google Scholar

23 

DeLano WL: The PyMOL molecular graphics system. 2002, http://www.pymol.org/May 30–2017

24 

Humphrey W, Dalke A and Schulten K: VMD: Visual molecular dynamics. J Mol Graph. 14:33–38, 27-28. 1996. View Article : Google Scholar : PubMed/NCBI

25 

Turner PJ: XMGRACE, Version 5.1.19. Center for Coastal and Land-Margin Research. Oregon Graduate Institute of Science and Technology; Beaverton, OR: 2005

26 

Zhao FL, Yang GH, Xiang S, Gao DD and Zeng C: In silico analysis of the effect of mutation on epidermal growth factor receptor in non-small-cell lung carcinoma: From mutational analysis to drug designing. J Biomol Struct Dyn. 35:427–434. 2017. View Article : Google Scholar : PubMed/NCBI

27 

Doss GP, Rajith B, Chakraborty C, NagaSundaram N, Ali SK and Zhu H: Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. Sci Rep. 4:58682014.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Peng XN, Wang J and Zhang W: Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma. Oncol Lett 14: 2249-2253, 2017.
APA
Peng, X., Wang, J., & Zhang, W. (2017). Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma. Oncology Letters, 14, 2249-2253. https://doi.org/10.3892/ol.2017.6387
MLA
Peng, X., Wang, J., Zhang, W."Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma". Oncology Letters 14.2 (2017): 2249-2253.
Chicago
Peng, X., Wang, J., Zhang, W."Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma". Oncology Letters 14, no. 2 (2017): 2249-2253. https://doi.org/10.3892/ol.2017.6387
Copy and paste a formatted citation
x
Spandidos Publications style
Peng XN, Wang J and Zhang W: Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma. Oncol Lett 14: 2249-2253, 2017.
APA
Peng, X., Wang, J., & Zhang, W. (2017). Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma. Oncology Letters, 14, 2249-2253. https://doi.org/10.3892/ol.2017.6387
MLA
Peng, X., Wang, J., Zhang, W."Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma". Oncology Letters 14.2 (2017): 2249-2253.
Chicago
Peng, X., Wang, J., Zhang, W."Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non‑small cell lung carcinoma". Oncology Letters 14, no. 2 (2017): 2249-2253. https://doi.org/10.3892/ol.2017.6387
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team